- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06219239
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
January 12, 2024 updated by: Jun Shi, Institute of Hematology & Blood Diseases Hospital, China
Evaluation of the Safety and Efficacy of KL003 Gene Therapy in Patients With Transfusion-dependent β-thalassemia With No Conditioning Regimen
This is a non-randomized, open-label, single-dose study.
The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells transfusion in subjects with β-thalassemia major.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
3
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jun Shi, PhD
- Phone Number: 13752253515
- Email: shijun@ihcams.ac.cn
Study Contact Backup
- Name: Zhen Gao, MD
- Email: gaozhen@ihcams.ac.cn
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Recruiting
- Institute of Hematology & Blood Diseases Hospital
-
Contact:
- Jun Shi
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female age between 3-35 years
- Diagnosis of transfusion-dependent β-thalassemia and a history of at least 100 mL/kg/year of pRBCs or ≥8 transfusions of pRBCs per year for the prior 2 years
- Documented baseline, or pretransfusion, Hb level≤7 g/dL
- Karnofsky performance status ≥70 for subjects≥16 years of age; Lansky performance status of ≥70 for subjects<16 years of age
- Eligible to undergo auto-HSCT
- Willing and able to follow the research procedures and conditions, with good compliance
- Willing to receive at least the 2 years follow-up and maintain detailed medical records, including transfusion history
- Subject and/or legal guardians voluntarily participated in this clinical trial and signed the informed consent form, and can complete all follow-ups in accordance with the protocol requirements
Exclusion Criteria:
- Presence of clear contraindications for hematopoietic stem cell collection
- Diagnosis of composite α thalassemia
- A white blood cell (WBC) count <3×10^9/L, and/or platelet count <100×10^9/L not related to hypersplenism
- Subjects with severe iron overload at the time of screening: severe iron overload of the liver showed by MRI, serum ferritin ≥ 5000 ng/mL, or moderate to severe iron overload of the heart
- Any prior or current malignancy or myeloproliferative or significant immunodeficiency disorder
- Meet the criteria for allo-HSCT and with an identified willing donor with a full HLA match
- Prior receipt of gene therapy or allo-HSCT
- Subjects with any severe active fungal, bacterial, viral, tuberculosis or other infection, including active hepatitis B (defined as serum HBV-DNA ≥2000 IU/ml), active hepatitis C virus, HCV) infection, human immunodeficiency virus (HIV) antibody-positive or active syphilis patients, etc.
- Immediate family member (i.e. parent or siblings) with a known Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis)
- Diagnosis of a significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study
History of major organ damage including:
- Liver function test suggest AST or ALT levels >3× upper limit of normal (ULN);
- Total serum bilirubin value >2.5×ULN;if combined with Gilbert syndrome, total bilirubin >3×ULN and direct bilirubin value >2.5×ULN;
- History of bridging fibrosis, cirrhosis;
- Left ventricular ejection fraction <45%;
- New York Heart Association (NYHA) class III or IV congestive heart failure;
- Severe arrhythmia requiring medical treatment;
- Uncontrolled hypertension or unstable angina pectoris;
- Myocardial infarction or bypass or stent surgery within 12 months before drug administration;
- Valvular disease with clinical significance;
- Baseline calculated eGFR<60mL/min/1.73m2;
- Pulmonary function: FEV1/FVC<60% and/or diffusion capacity of carbon monoxide (DLco) <60% of prediction;
- Evidence of clinically significant pulmonary hypertension requiring medical intervention.
- Uncorrectable coagulation dysfunction or history of severe bleeding disorder
- Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician
- Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.)
- Participated in other clinical studies within 3 months prior to screening
- Inoculated live vaccine within 6 weeks prior to screening
- Pregnancy or breastfeeding women; Subjects or their sexual partners were unable to take medically recognized effective contraceptive measures during the 27-month study period
- The subjects or their parents would not comply with the study procedures outlined in the protocol
- The subjects received hydroxyurea or thalidomide or hypomethylating drugs within 3 months before hematopoietic stem cell collection
- Patients considered to be ineligible for the study by the investigator for reasons other than the above
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KL003 cell injection Drug Product
Traditional myeloablative conditioning regimen consists of Busulfan, which may increase the risk of irreversible pulmonary fibrosis, VOD, and infertility due to potential serious toxicity.
In this study, we intend to use genetic hematopoietic stem cells (lentivirus transduction) transfusion with no conditioning regimen, which could avoid toxicity due to chemotherapy drugs.
|
No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants who meet the definition of transfusion independence (TI) for at least 6 months
Time Frame: Up to 24 months post transplant
|
TI is defined as Hb ≥ 90.0 g/L after reinfusion and without disease-related routine blood transfusion for 6 months
|
Up to 24 months post transplant
|
The number, frequency and severity of adverse events (AE) after reinfusion of KL003 drug products
Time Frame: within 6 months
|
within 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 4, 2024
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
January 5, 2024
First Submitted That Met QC Criteria
January 12, 2024
First Posted (Estimated)
January 23, 2024
Study Record Updates
Last Update Posted (Estimated)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 12, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-KL003-004/01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transfusion-dependent Beta-Thalassemia
-
Agios Pharmaceuticals, Inc.Active, not recruitingTransfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United States, France, Canada, Malaysia, Germany, Netherlands, Bulgaria, United Kingdom, Turkey, Italy, Greece, United Arab Emirates, Brazil, Denmark, Lebanon, Saudi Arabia
-
Agios Pharmaceuticals, Inc.Active, not recruitingNon-Transfusion-dependent Alpha-Thalassemia | Non-Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United Kingdom, Malaysia, United States, Netherlands, Bulgaria, Turkey, Italy, Canada, Brazil, France, United Arab Emirates, Denmark, Greece, Lebanon, Saudi Arabia
-
Editas Medicine, Inc.RecruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
Vifor (International) Inc.Labcorp Corporation of America Holdings, IncCompletedBeta-Thalassemia | Non-transfusion-dependent ThalassemiaGreece, Israel, Italy, Lebanon, Thailand
-
bluebird bioActive, not recruitingTransfusion-dependent Beta-ThalassemiaUnited States, France, United Kingdom, Australia, Thailand, Italy, Germany, Greece
-
Sangamo TherapeuticsSanofiCompletedTransfusion Dependent Beta-thalassemiaUnited States
-
Novartis PharmaceuticalsCompletedBeta Thalassemia Transfusion DependentItaly
-
Institute of Hematology & Blood Diseases HospitalR&D Kanglin BiotechRecruitingTransfusion-dependent Beta-ThalassemiaChina
-
First Affiliated Hospital of Guangxi Medical UniversityGenmedicn Biopharma Ltd.RecruitingTransfusion Dependent Beta-ThalassemiaChina
-
Institute of Hematology & Blood Diseases Hospital...EdiGene Inc.; The Affiliated Hospital Of Guizhou Medical University; Zunyi Medical...Active, not recruitingTransfusion Dependent Beta-ThalassaemiaChina
Clinical Trials on KL003 cell injection Drug Product
-
Institute of Hematology & Blood Diseases HospitalR&D Kanglin BiotechRecruitingTransfusion-dependent Beta-ThalassemiaChina
-
Kanglin Biotechnology (Hangzhou) Co., Ltd.Not yet recruitingTransfusion-dependent Beta-ThalassemiaChina
-
Nantes University HospitalUnknown
-
Nantes University HospitalTerminatedHepatocellular CarcinomaFrance
-
Harbour BioMed (Guangzhou) Co. Ltd.Not yet recruiting
-
Alaunos TherapeuticsRecruitingGynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Adenocarcinoma of Lung | Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Ovary Neoplasm | Adenosquamous Cell Lung CancerUnited States
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisRecruitingArtemis (DCLRE1C ) Deficient Severe Combined ImmunodeficiencyFrance
-
Rigshospitalet, DenmarkWithdrawnRespiratory Tract DiseasesDenmark